Vertex nixes its effort to develop a therapy for a rare genetic disorder that affects the lungs and liver, but analysts see a drop in the stock price as a buying opportunity.
Why are analysts split on Moderna?
Moderna shares came under sell-off pressure in the last one week amid patent protection waiving talks. Despite this, some analysts remain bullish on the stock, thanks to the company’s latest guidance.
Kelvin Ong | Financial writer, Singapore | Publication date: 2021-05-12T15:40:31+0100
Moderna Inc (NASDAQ: MRNA) share price stays down a week after the US government indicated its support for the lifting of Covid-19 vaccine patent protections
The company announced on Wednesday (12 May 2021) a new supply agreement with the Australian government for 25 million doses
Despite the ongoing sell-off, two analysts raised their price targets on the stock, citing its Q1 performance
Moderna Reports First Profit Ever but Misses Revenue Estimates — Analysts Cautiously Optimistic gobankingrates.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gobankingrates.com Daily Mail and Mail on Sunday newspapers.